InvestmentUpdated on 28 April 2026
Accelerate preclinical and clinical development
About
NanoVet is seeking investment to accelerate the preclinical and clinical development of its lead programs and to expand its nanobody platform into additional animal health indications. Capital will support regulatory advancement, pipeline expansion, and manufacturing readiness, with a strong value proposition based on first-in-class nanobody applications in veterinary medicine and a scalable platform with translational potential into human therapeutics.
Similar opportunities
Expertise
Nanobody engineering and translational biologics development
Nicolás Galmarini
CEO & Co-founder at NanoVet Biotech
Pamplona, Spain
Partnership
With Animal Health and Biotech companies
Nicolás Galmarini
CEO & Co-founder at NanoVet Biotech
Pamplona, Spain